EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Vaccine

• Publication date

  2008-06-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2008.03.083PMID 18502002
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of HIV Vaccine-Induced Cell-Mediated Immunity in HIV-Seronegative Clinical Trial Participants Using an Optimized and Validated Enzyme-Linked Immunospot Assay

  2007cited by this paper
• A functional human IgM response to HIV-1 Env after immunization with NYVAC HIV C

  2007cited by this paper
• Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype

  2007cited by this paper
• Test of HIV incidence shows continuing HIV transmission in homosexual/bisexual men in England and Wales.

  2001cited by this paper
• Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.

  2000cited by this paper
• Characterization of a Virtually Full-Length Human Immunodeficiency Virus Type 1 Genome of a Prevalent Intersubtype (C/B′) Recombinant Strain in China

  2000cited by this paper
• Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

  1998cited by this paper

• Understanding the performance of HIV-1 viral vector vaccines: adenovirus and poxvirus case studies

  2026cites this paper
• Use of the Highly Attenuated Vaccinia Virus, Strain NYVAC, as Recombinant Vector for Construction Vaccine Against HIV Infection

  2025cites this paper
• Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

  2020cites this paper
• Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial

  2019cites this paper
• Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost

  2018cites this paper
• Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates

  2018cites this paper
• Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC

  2018cites this paper
• Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways

  2017cites this paper
• HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Prima

  2017cites this paper
• Effect of the Modification of p24 Peptide Antigen on Dendritic Cell Uptake and T Cell Activation.

  2017cites this paper
• Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial

  2017cites this paper
• Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.

  2016cites this paper
• Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

  2016cites this paper
• Streamlining Heterologous DNA-Prime and NYVAC / Protein-Boost HIV Vaccine Regimens in 1 Rhesus Macaques by Employing Improved Antigens 2 3

  2016cites this paper
• Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines - A review from a regulatory perspective.

  2016cites this paper
• Searching for an hiv vaccine: a heterologous prime-boost system using replicating vaccinia virus and plant-produced virus-like particles

  2016cites this paper
• Immune correlates of vaccine protection against HIV-1 acquisition

  2015cites this paper
• Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates

  2015cites this paper
• The Evolution of Poxvirus Vaccines

  2015cites this paper
• Title Employing Improved Antigens Allows Streamlining of Heterologous DNA-Prime and NYVAC / Protein-Boost HIV Vaccine Regimens in Rhesus Macaques Running title : Improved HIV Antigens and Delivery Schedules in Macaques

  2015cites this paper
• Interleukin-1- and Type I Interferon-Dependent Enhanced Immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef Vaccine Vector with Dual Deletions of Type I and Type II Interferon-Binding Proteins

  2015cites this paper
• Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

  2014cites this paper
• Memory CD8(+) T cells elicited by HIV-1 lipopeptide vaccines display similar phenotypic profiles but differences in term of magnitude and multifunctionality compared with FLU- or EBV-specific memory T cells in humans.

  2014cites this paper
• Safety and effi cacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial

  2014cites this paper
• PedVacc 002: A phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi

  2014cites this paper
• Safety and effi cacy of the peptide-based therapeutic vaccine for HIV-1 , Vacc-4 x : a phase 2 randomised , double-blind , placebo-controlled trial

  2014cites this paper
• Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles

  2014cites this paper
• Enhancing poxvirus vectors vaccine immunogenicity

  2014cites this paper
• HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

  2014cites this paper
• Prospective Surveillance for Cardiac Adverse Events in Healthy Adults Receiving Modified Vaccinia Ankara Vaccines: A Systematic Review

  2013cites this paper
• First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).

  2013cites this paper
• Novel directions in HIV-1 vaccines revealed from clinical trials.

  2013cites this paper
• Procédé de vaccination contre le vih

  2013cites this paper
• Rekombinantní vakcíny proti solidním a hematologickým nádorům: vývoj a stanovení jejich účinnosti

  2013cites this paper
• Nonreplicating vectors in HIV vaccines.

  2013influential citation
• Viral vectors for vaccine applications

  2013cites this paper
• Optimizing cellular immunity against HIV-1 Gag and preventing suppression by HIV-1 gp120

  2012cites this paper
• Systems biology in the development of HIV vaccines.

  2012cites this paper
• Poxvirus vectors as HIV/AIDS vaccines in humans

  2012cites this paper
• A vaccinia virus renaissance

  2012cites this paper
• Altering an Artificial Gagpolnef Polyprotein and Mode of ENV Co-Administration Affects the Immunogenicity of a Clade C HIV DNA Vaccine

  2012cites this paper
• Chapter 8 – The design of a global HIV vaccine1

  2012cites this paper
• NYVAC-C in Mice of the HIV/AIDS Vaccine Candidate Improves Adaptive and Memory Responses Block Interferon Type I and II Pathways Removal of Vaccinia Virus Genes That

  2012cites this paper
• Removal of Vaccinia Virus Genes That Block Interferon Type I and II Pathways Improves Adaptive and Memory Responses of the HIV/AIDS Vaccine Candidate NYVAC-C in Mice

  2012cites this paper
• MVA and NYVAC as vaccines against emergent infectious diseases and cancer.

  2011cites this paper
• ExposureMassive TCR Renewal after Antigen Cells Provides the Mechanistic Basis for Large TCR Diversity of Virus-Specific CD8 T

  2011cites this paper
• Accelerating the development of an AIDS vaccine: the AIDS vaccine for Asia Network (Avan).

  2011cites this paper
• Improved NYVAC-Based Vaccine Vectors

  2011cites this paper
• Exposure Massive TCR Renewal after Antigen Cells Provides the Mechanistic Basis for Large TCR Diversity of Virus-Specific CD 8 T

  2011cites this paper
• Innate immune recognition of poxviral vaccine vectors

  2011cites this paper
• A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses

  2011cites this paper
• Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion.

  2011cites this paper
• Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

  2011cites this paper
• Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors

  2011cites this paper
• Large TCR Diversity of Virus-Specific CD8 T Cells Provides the Mechanistic Basis for Massive TCR Renewal after Antigen Exposure

  2011cites this paper
• DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell Responses in Intestinal Mucosa

  2011cites this paper
• Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors

  2011cites this paper
• Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate

  2010cites this paper
• HIV vaccine could use a little help

  2010cites this paper
• Vaccines for Human Immunodeficiency Virus-1 Infection

  2010cites this paper
• Poxvirus vector-based HIV vaccines

  2010cites this paper
• Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1

  2010cites this paper
• Comparison of Human and Rhesus Macaque T-Cell Responses Elicited by Boosting with NYVAC Encoding Human Immunodeficiency Virus Type 1 Clade C Immunogens

  2009cites this paper
• Preclinical Evaluation of the Immunogenicity of C-Type HIV-1-Based DNA and NYVAC Vaccines in the Balb/C Mouse Model

  2009cites this paper
• Attenuated poxvirus vectors MVA and NYVAC as promising vaccine cadidates against HIV/AIDS

  2009cites this paper
• A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers

  2009cites this paper
• Viral vectors, in innate and adaptive immunity

  2009influential citation
• Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.

  2009cites this paper
• Vaccinia Virus K1L and C7L Inhibit Antiviral Activities Induced by Type I Interferons

  2009cites this paper
• Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax

  2008cites this paper
• EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.

  2008cites this paper